Price alert —
Sign in to get a one-time email the moment JNJ crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · JNJ
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $nanB | $nanB | $nanB | — | nan% | nan% |
| 2026-03-31 | $24.1B | $5.2B | $6.4B | $1.5B | 21.8% | 26.6% |
| 2025-12-31 | $24.6B | $5.1B | $5.6B | $5.5B | 20.8% | 22.8% |
| 2025-09-30 | $24.0B | $5.2B | $7.1B | $8.0B | 21.5% | 29.6% |
| 2025-06-30 | $23.7B | $5.5B | $6.7B | $2.5B | 23.3% | 28.3% |
| 2025-03-31 | $21.9B | $11.0B | $6.2B | $3.4B | 50.2% | 28.3% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare JNJ vs peers
Line JNJ up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with JNJ
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-07-15 | 2.90 | 2.85 | +1.6% | +1.2% |
| 2026-04-14 | 2.70 | 2.68 | +0.8% | -0.6% |
| 2026-01-21 | 2.46 | 2.46 | -0.1% | +0.2% |
| 2025-10-14 | 2.80 | 2.76 | +1.5% | +0.2% |
| 2025-07-16 | 2.77 | 2.68 | +3.2% | -1.1% |
| 2025-04-15 | 2.77 | 2.58 | +7.4% | +0.2% |
| 2025-01-22 | 2.04 | 2.01 | +1.4% | +0.9% |
| 2024-10-15 | 2.42 | 2.21 | +9.7% | +0.1% |
| 2024-07-17 | 2.82 | 2.70 | +4.3% | -0.7% |
| 2024-04-16 | 2.71 | 2.65 | +2.3% | +0.2% |
| 2024-01-23 | 2.29 | 2.28 | +0.4% | -0.5% |
| 2023-10-17 | 2.66 | 2.52 | +5.5% | -2.1% |
| 2023-07-20 | 2.80 | 2.62 | +6.9% | +1.1% |
| 2023-04-18 | 2.68 | 2.50 | +7.2% | +0.9% |
| 2023-01-24 | 2.35 | 2.24 | +5.1% | +0.7% |
| 2022-10-18 | 2.55 | 2.49 | +2.6% | -0.8% |
| 2022-07-19 | 2.59 | 2.55 | +1.6% | -0.6% |
| 2022-04-19 | 2.67 | 2.57 | +4.1% | +0.4% |
| 2022-01-25 | 2.13 | 2.12 | +0.5% | +0.5% |
| 2021-10-19 | 2.60 | 2.35 | +10.5% | -0.1% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| LLY | — | 41.8 | 26.3 | — | 30.1 | — | 82.8% | 55.5% | 169.9% | — |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ ★ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | — | 36.0 | 13.2 | — | 12.1 | 6.9 | 76.7% | 4.9% | — | — |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | — | 19.1 | 8.8 | — | 7.6 | — | 74.8% | 5.4% | -10.1% | — |
| TMO | — | 29.2 | 19.5 | — | 21.1 | — | 40.9% | 6.2% | 11.3% | — |
| ABT | — | 28.2 | 16.6 | — | 17.1 | 3.4 | 56.8% | 13.0% | -47.5% | — |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 34.08%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 213,385,546 | 8.86% |
| Vanguard Capital Management LLC | 156,605,370 | 6.51% |
| State Street Corporation | 133,476,288 | 5.54% |
| Vanguard Portfolio Management LLC | 63,514,436 | 2.64% |
| JPMORGAN CHASE & CO | 63,096,344 | 2.62% |
| Geode Capital Management, LLC | 59,164,862 | 2.46% |
| Morgan Stanley | 44,721,167 | 1.86% |
| State Farm Mutual Automobile Insuran | 31,590,952 | 1.31% |
| Northern Trust Corporation | 29,319,669 | 1.22% |
| Bank of America Corporation | 25,516,697 | 1.06% |
Insider activity · 90d
9 buys / 1 sells · ratio 9.0 · Finnhub
- Wengel Kathryn E M 32,965
- Wengel Kathryn E SELL 114,288 @ $241.15
- Wengel Kathryn E M 124,288 @ $115.67
- Woods Eugene A. BUY 6,412 @ $232.79
- Pinto Daniel E BUY 2,321 @ $232.79
- HEWSON MARILLYN A BUY 15,792 @ $232.79
- REED JOHN C M 0
- REED JOHN C F 24,911 @ $229.85
- REED JOHN C M 35,913
- West Nadja BUY 7,730
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-07-15 | 8-K | view · |
| 4 | 2026-06-12 | FORM 4 | view · |
| 4 | 2026-06-11 | FORM 4 | view · |
| 4 | 2026-06-11 | FORM 4 | view · |
| 4 | 2026-06-11 | FORM 4 | view · |
| 13F-HR | 2026-05-13 | Institutional holdings (13F) | view · |
| 4 | 2026-05-04 | FORM 4 | view · |
| 8-K | 2026-04-28 | 8-K | view · |
| 4 | 2026-04-27 | FORM 4 | view · |
| 4 | 2026-04-27 | FORM 4 | view · |
| 4 | 2026-04-27 | FORM 4 | view · |
| 4 | 2026-04-27 | FORM 4 | view · |
| 4 | 2026-04-27 | FORM 4 | view · |
| 4 | 2026-04-27 | FORM 4 | view · |
| 4 | 2026-04-27 | FORM 4 | view · |
| 4 | 2026-04-27 | FORM 4 | view · |
| 4 | 2026-04-27 | FORM 4 | view · |
| 4 | 2026-04-27 | FORM 4 | view · |
| 4 | 2026-04-27 | FORM 4 | view · |
| 10-Q | 2026-04-22 | 10-Q | view · |
| 8-K | 2026-04-14 | 8-K | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| DEF 14A | 2026-03-11 | DEF 14A | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-02-23 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 13F-HR | 2026-02-13 | Institutional holdings (13F) | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 10-K | 2026-02-11 | 10-K | view · |
| 4 | 2026-02-10 | FORM 4 | view · |
| 4 | 2026-02-09 | FORM 4 | view · |
| 4 | 2026-02-09 | FORM 4 | view · |
| 4 | 2026-02-06 | FORM 4 | view · |
| 4 | 2026-01-28 | FORM 4 | view · |
| 8-K | 2026-01-21 | 8-K | view · |
| 4 | 2025-12-11 | FORM 4 | view · |
| 4 | 2025-12-11 | FORM 4 | view · |
| 4 | 2025-12-11 | FORM 4 | view · |
| 4 | 2025-12-01 | FORM 4 | view · |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and re…
Options picks · JNJ
ITM + OTM ideas from the latest scanLoading…
Congress trades · JNJ
STOCK Act disclosuresLoading…
SEC filings & insiders · JNJ
EDGAR · liveLoading…
Holders · JNJ
Institutions & insider activityLoading…